Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore

Human Psychopharmacology

Volumn 19, Issue 4, 2004, Pages 259-264

  Luo, Nan ^a   Koh, Yvonne ^a   Tan, Chay Hoon ^a,b   Kua, Ee Heok ^b   Li, Shu Chuen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Asian; Drug utilization; Risperidone; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; FLUPENTIXOL; HALOPERIDOL; HYPNOTIC AGENT; NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRANQUILIZER; TRIFLUOPERAZINE;

ADOLESCENT; ADULT; AGED; CONTROLLED STUDY; DRUG USE; FEMALE; GENERAL HOSPITAL; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGAPORE;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALS, CHRONIC DISEASE; HOSPITALS, UNIVERSITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SINGAPORE;

EID: 3042850290     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.585     Document Type: Review

References (19)

1. Binder R, Levy R. 1981. Extrapyramidal reactions in Asians. Am J Psychiatry 138: 1243-1244.
2. Brown C, Markowitz J, Moore T, Parker N. 1999. Atypical antipsychotics - Part II: adverse effects, drug interactions, and costs. Ann Pharmacother 33: 210-217.
3. Chong S, Sachdev P. Mahendran R, Chua H. 2000. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state pyschiatric hospital in Singapore. Aust N Z J Psychiatry 34: 988-991.
4. Chong S, Yap H, Low B, et al. 1999. Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore. Singapore Med J 40: 41-43.
5. Chouinard G, Jones B, Remington G, et al. 1993. A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25-40.
6. Davis A, Adena M, Kekes N, Catts S, Lamber T, Schweitzer I. 1998. Risperidone versus haloperidol: I - Meta-analysis of efficacy and safety. Clin Ther 20: 58-71.
7. Hunter R, Joy C, Kennedy E, Gilbody S, Song F. 2003. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev CD000440.
8. Iskedjian M, Hux M, Remington G. 1998. The Canadian experience with risperidone for the treatment of schizophrenia: an overview. J Psychiatry Neurosci 23: 229-239.
9. Kasper S, Jones M, Duchesne I. 2001. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 16: 189-196.
10. Katz I, Jeste D, Mintzer J, Clyde C, Napolitano J, Brecher M. 1999. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 60: 107-115.
11. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. 2000. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev CD000440.
12. Love R, Conley R, Kelly D, Bartko J. 1999. A dose-outcome analysis of risperidone. J Clin Psychiatry 60: 771-775.
13. Love R, Nelson M. 2000. Pharmacology and clinical experience with risperidone. Expert Opin Pharmacother 1: 1441-1453.
14. Marder S, Glynn S, Wirshing W, et al. 2003. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year out-comes. Am J Psychiatry 160: 1405-1412.
15. Marder S, Meibach R. 1994. Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825-835.
16. Peuskens J. 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166: 712-726.
17. Product Information. Risperdal(R) risperidone. Janssen Pharmaceutica, Titusville, NJ, (PI revised 05/1999) reviewed 02/2003.
18. Williams R. 2001. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 62: 282-289.
19. Yap H, Mahendran R, Lim D, et al. 2001. Risperidone in the treatment of first episode psychosis. Singapore Med J 42: 170-173.